Vygenerované: 08.12.2025 21:39:04
Súhrn: TOPLINE: Patients with extensive-stage small cell lung cancer (SCLC) receiving immunochemotherapy before 3:00 PM showed significantly longer overall survival of 18 8 months for later treatment - Researchers conducted a retrospective analysis of 397 patients with extensive-stage SCLC who received first-line anti-PD-L1 plus chemotherapy between May 2019 and October 2023 at Hunan Cancer Hospital.
Doplnenie: Early administration was associated with improved progression-free survival of 7.